66382 Federal Register / Vol. 75, No. 208 / Thursday, October 28, 2010 / Notices 

Advisory Committee Information Line, 

1–800–741–8138 (301–443–0572 in the 

Washington, DC area), code 

8732310001. Please call the Information 

Line for up-to-date information on this 

meeting. A notice in the Federal 

Register about last minute modifications 

that impact a previously announced 

advisory committee meeting cannot 

always be published quickly enough to 

provide timely notice. Therefore, you 

should always check the Agency’s Web 

site and call the appropriate advisory 

committee hot line/phone line to learn 

about possible modifications before 

coming to the meeting. 

Agenda: The Pediatric Advisory 

Committee (PAC) will meet to discuss 

donor and banked human milk. FDA is 

convening the meeting to obtain and 

discuss information and data that will 

provide the Agency with a better 

understanding of current practices, and 

potential benefits and risks associated 

with the donation and banking of 

human milk. 

FDA recognizes the benefits 

associated with breastfeeding, and is 

focusing this meeting on issues related 

to banking human milk. Human milk is 

banked for use by infants in need of 

donated milk. The agenda for the 

meeting will include presentations and 

discussions on the benefits and risks of 

human milk banking practices as they 

relate to pre-term and term infant 

populations. Topics will include, but 

not be limited to, infectious disease 

risks, State regulations and current 

practices in donor and human milk 

banking. 

FDA intends to make background 

material available to the public no later 

than 2 business days before the meeting. 

If FDA is unable to post the background 

material on its Web site prior to the 

meeting, the background material will 

be made publicly available at the 

location of the advisory committee 

meeting, and the background material 

will be posted on FDA’s Web site after 

the meeting. Background material is 

available at http://www.fda.gov/

AdvisoryCommittees/Calendar/default.

htm. Scroll down to the appropriate 

advisory committee link. 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person on or before November 29, 2010. 

Oral presentations from the public will 

be scheduled between approximately 1 

p.m. and 2 p.m. Those individuals 

interesting in making formal oral 

presentations should notify the contact 

person and submit a brief statement of 

the general nature of the evidence or 

arguments they wish to present, the 

names and addresses of proposed 

participants, and an indication of the 

approximate time requested to make 

their presentation on or before 

November 18, 2010. Time allotted for 

each presentation may be limited. If the 

number of registrants requesting to 

speak is greater than can be reasonably 

accommodated during the scheduled 

open public hearing session, FDA may 

conduct a lottery to determine the 

speakers for the scheduled open public 

hearing session. The contact person will 

notify interested persons regarding their 

request to speak by November 19, 2010. 

Comments: FDA is opening a docket 

to allow for additional public comments 

to be submitted to the Agency on the 

issues before the Pediatric Advisory 

Committee beginning October 28, 2010, 

and closing January 6, 2011. All 

comments received on or before 

November 29, 2010, will be provided to 

the committee members. All comments 

received after November 29, 2010, will 

be taken into consideration by the 

Agency. Interested persons are 

encouraged to use the docket to submit 

either electronic or written comments 

regarding this meeting (see ADDRESSES). 

Submit electronic comments to http://

www.regulations.gov. Submit written 

comments to the Division of Dockets 

Management, Food and Drug 

Administration, 5630 Fishers Lane, rm. 

1061, Rockville, MD 20852. It is only 

necessary to send one set of comments. 

It is no longer necessary to send two 

copies of mailed comments. Identify 

comments with the docket number 

found in brackets in the heading of this 

document. Received comments may be 

seen in the Division of Dockets 

Management between 9 a.m. and 4 p.m., 

Monday through Friday. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

Agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact Walter 

Ellenberg, at least 7 days in advance of 

the meeting. 

FDA is committed to the orderly 

conduct of its advisory committee 

meetings. Please visit our Web site at 

http://www.fda.gov/

AdvisoryCommittees/

AboutAdvisoryCommittees/

ucm111462.htm for procedures on 

public conduct during advisory 

committee meetings. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2). 

Dated: October 25, 2010. 

Jill Hartzler Warner, 

Acting Associate Commissioner for Special 

Medical Programs. 

[FR Doc. 2010–27283 Filed 10–27–10; 8:45 am] 

BILLING CODE 4160–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2010–N–0001] 

Request for Notification From Industry 

Organizations Interested in 

Participating in the Selection Process 

for Nonvoting Industry 

Representatives on Public Advisory 

Committees and Panels and Request 

for Nonvoting Industry 

Representatives on Public Advisory 

Committees and Panels 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is requesting that 

any industry organization interested in 

participating in the selection of 

nonvoting industry representatives to 

serve on the National Mammography 

Quality Assurance Advisory Committee 

(NMQAAC) and certain device panels of 

the Medical Devices Advisory 

Committee (MDAC) in the Center for 

Devices and Radiological Health (CDRH) 

notify FDA in writing. A nominee may 

either be self nominated or nominated 

by an organization to serve as a 

nonvoting industry representative. 

Nominations will be accepted for 

current vacancies effective with this 

notice. 

DATES: Any industry organizations 

interested in participating in the 

selection of an appropriate nonvoting 

member to represent industry interests 

must send a letter stating that interest to 

the FDA by November 29, 2010, for the 

vacancies listed in this document. 

Concurrently, nomination materials for 

prospective candidates should be sent to 

FDA by November 29, 2010. 

ADDRESSES: Send all letters of interest 

and nominations to Margaret J. Ames 

(see FOR FURTHER INFORMATION CONTACT). 

FOR FURTHER INFORMATION CONTACT: 

Margaret J. Ames, Center for Devices 

and Radiological Health, Food and Drug 

Administration, 10903 New Hampshire 

Ave., Bldg. 66, rm. 5234, Silver Spring, 


emcdonald on DSK2BSOYB1PROD with NOTICES
Federal Register / Vol. 75, No. 208 / Thursday, October 28, 2010 / Notices 66383 

MD 20993, 301–796–5960, e-mail: 

margaret.ames@fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: The 

agency intends to add nonvoting 

industry representatives to the following 

advisory committees: 

I. CDRH—Various Committees and 

Panels 

A. National Mammography Quality 

Assurance Advisory Committee 

(NMQAAC) 

The Mammography Quality Standards 

Reauthorization Act of 2004 (Pub. L. 

108–365) requires the addition of at 

least two industry representatives with 

expertise in mammography equipment 

to the NMQAAC. 

B. Medical Devices Advisory Committee 

(MDAC) 

Section 520(f)(3) of the Federal Food, 

Drug, and Cosmetic Act (FD&C Act) (21 

U.S.C. 360j(f)(3)), as amended by the 

Medical Device Amendments of 1976, 

provides that each medical device panel 

include one nonvoting member to 

represent the interests of the medical 

device manufacturing industry. 

II. CDRH—Committee and Panels 

Functions 

FDA is requesting nominations for 

nonvoting members representing 

industry interests for vacancies listed in 

table 1 of this document as follows: 

TABLE 1—NOMINATIONS REQUESTED

FOR NONVOTING MEMBERS REPRESENTING INDUSTRY INTERESTS ON

PUBLIC ADVISORY COMMITTEES AND

PANELS

Committee name or 

panel 

Approximate date 

needed 

NMQAAC ...................... February 1, 2011. 

Anesthesiology and 

Respiratory Therapy 

Devices Panel.

December 1, 2011. 

General and Plastic 

Surgery Devices 

Panel.

September 1, 2011. 

A. NMQAAC 

The functions of the NMQAAC are to 

advise FDA on: (1) Developing 

appropriate quality standards and 

regulations for mammography facilities; 

(2) developing appropriate standards 

and regulations for bodies accrediting 

mammography facilities under this 

program; (3) developing regulations 

with respect to sanctions; (4) developing 

procedures for monitoring compliance 

with standards; (5) establishing a 

mechanism to investigate consumer 

complaints; (6) reporting new 

developments concerning breast 

imaging which should be considered in 

the oversight of mammography 

facilities; (7) determining whether there 

exists a shortage of mammography 

facilities in rural and health 

professional shortage areas and 

determining the effects of personnel on 

access to the services of such facilities 

in such areas; (8) determining whether 

there will exist a sufficient number of 

medical physicists after October 1, 1999; 

and (9) determining the costs and 

benefits of compliance with these 

requirements. 

B. Certain Panels of the Medical Devices 

Advisory Committee 

The medical device panels perform 

the following functions: (1) Review and 

evaluate data on the safety and 

effectiveness of marketed and 

investigational devices and make 

recommendations for their regulation; 

(2) advise the Commissioner of Food 

and Drugs (the Commissioner) regarding 

recommended classification or 

reclassification of these devices into one 

of three regulatory categories; (3) advise 

on any possible risks to health 

associated with the use of devices; (4) 

advise on formulation of product 

development protocols; (5) review 

premarket approval applications for 

medical devices; (6) review guidelines 

and guidance documents; (7) 

recommend exemption to certain 

devices from the application of portions 

of the FD&C Act; (8) advise on the 

necessity to ban a device; (9) respond to 

requests from the agency to review and 

make recommendations on specific 

issues or problems concerning the safety 

and effectiveness of devices; and (10) 

make recommendations on the quality 

in the design of clinical studies 

regarding the safety and effectiveness of 

marketed and investigational devices. 

III. Selection Procedure 

Any industry organization interested 

in participating in the selection of an 

appropriate nonvoting member to 

represent industry interests should send 

a letter stating that interest to the 

contact person (see FOR FURTHER

INFORMATION CONTACT) within 30 days of 

publication of this notice. Within the 

subsequent 30 days, FDA will send a 

letter to each organization that has 

expressed an interest, attaching a 

complete list of all such organizations, 

and a list of all nominees along with 

their current re ́sume ́s. The letter will 

also state that it is the responsibility of 

the interested organizations to confer 

with one another and to select a 

candidate, within 60 days after the 

receipt of the FDA letter, to serve as the 

nonvoting member to represent industry 

interests for a particular committee or 

device panel. The interested 

organizations are not bound by the list 

of nominees in selecting a candidate. 

However, if no individual is selected 

within the 60 days, the Commissioner of 

Food and Drugs will select the 

nonvoting member to represent industry 

interests. 

IV. Qualifications 

A. NMQAAC 

Persons nominated for membership as 

an industry representative on the 

NMQAAC must meet the following 

criteria: (1) Demonstrate expertise in 

mammography equipment; and (2) be 

able to discuss equipment specifications 

and quality control procedures affecting 

mammography equipment. The industry 

representative must be able to represent 

the industry perspective on issues and 

actions before the advisory committee, 

serve as liaison between the committee 

and interested industry parties, and 

facilitate dialogue with the advisory 

committee on mammography equipment 

issues. 

B. MDAC 

Persons nominated for the device 

panels should be full-time employees of 

firms that manufacture products that 

would come before the panel, or 

consulting firms that represent 

manufacturers, or have similar 

appropriate ties to industry. 

V. Application Procedure 

Individuals may self nominate and/or 

an organization may nominate one or 

more individuals to serve as a nonvoting 

industry representative. Within 30 days, 

the following information should be 

sent to the FDA contact person (see FOR

FURTHER INFORMATION CONTACT): A 

current curriculum vitae of each 

nominee, current business and/or home 

address, telephone number, e-mail 

address, and the name of the committee 

or device panel of interest. FDA will 

forward all nominations to the 

organizations expressing interest in 

participating in the selection process for 

the committee or panel. (Persons who 

nominate themselves as nonvoting 

industry representatives will not 

participate in the selection process). 

FDA has a special interest in ensuring 

that women, minority groups, 

individuals with physical disabilities, 

and small businesses are adequately 

represented on its advisory committees, 

and therefore, encourages nominations 

for appropriately qualified candidates 

from these groups. 

This notice is issued under the 

Federal Advisory Committee Act (5 


emcdonald on DSK2BSOYB1PROD with NOTICES
66384 Federal Register / Vol. 75, No. 208 / Thursday, October 28, 2010 / Notices 

U.S.C. app. 2) and 21 CFR part 14, 

relating to advisory committees. 

Dated: October 22, 2010. 

Jill Hartzler Warner, 

Acting Associate Commissioner for Special 

Medical Programs. 

[FR Doc. 2010–27230 Filed 10–27–10; 8:45 am] 

BILLING CODE 4160–01–P 

DEPARTMENT OF HOUSING AND 

URBAN DEVELOPMENT 

[Docket No. FR–5383–N–23] 

Notice of Proposed Information 

Collection for Public Comment; 

Exigent Health and Safety Deficiency 

Correction Certification 

AGENCY: Office of the Assistant 

Secretary for Public and Indian 

Housing, HUD. 

ACTION: Notice. 

SUMMARY: The proposed information 

collection requirement described below 

will be submitted to the Office of 

Management and Budget (OMB) for 

review, as required by the Paperwork 

Reduction Act. The Department is 

soliciting public comments on the 

subject proposal. 

DATES: Comments Due Date: December 

27, 2010. 

ADDRESSES: Interested persons are 

invited to submit comments regarding 

this proposal. Comments should refer to 

the proposal by name/or OMB Control 

number and should be sent to: Colette 

Pollard, Department Reports 

Management Officer, Office of the Chief 

Information Officer, Department of 

Housing and Urban Development, 451 

7th Street, SW., Room 4160, 

Washington, DC 20410–5000; telephone 

202.402.3400, (this is not a toll-free 

number) or email Colette_Pollard@ 

hud.gov. Persons with hearing or speech 

impairments may access this number 

through TTY by calling the toll-free 

Federal Information Relay Service at 

(800) 877–8339. (Other than the HUD 

USER information line and TTY 

numbers, telephone numbers are not 

toll-free.), or e-mail Ms. 

Colette_Pollard@hud.gov. Persons with 

hearing or speech impairments may 

access this number through TTY by 

calling the toll-free Federal Information 

Relay Service at (800) 877–8339. (Other 

than the HUD USER information line 

and TTY numbers, telephone numbers 

are not toll-free.) 

FOR FURTHER INFORMATION CONTACT: 

Arlette Mussington, Office of Policy, 

Programs and Legislative Initiatives, 

PIH, Department of Housing and Urban 

Development, 451 Seventh Street, SW., 

(L’Enfant Plaza, Room 2206), 

Washington, DC 20410; telephone: 202– 

402–4109, (this is not a toll-free 

number) for copies of the proposed 

forms and other available documents. 

SUPPLEMENTARY INFORMATION: The 

Department will submit the proposed 

information collection to OMB for 

review, as required by the Paperwork 

Reduction Act of 1995 (44 U.S.C. 

Chapter 35, as amended). This Notice is 

soliciting comments from members of 

the public and affected agencies 

concerning the proposed collection of 

information to: (1) Evaluate whether the 

proposed collection of information is 

necessary for the proper performance of 

the functions of the agency, including 

whether the information will have 

practical utility; (2) evaluate the 

accuracy of the agency’s estimate of the 

burden of the proposed collection of 

information; (3) enhance the quality, 

utility, and clarity of the information to 

be collected; and (4) minimize the 

burden of the collection of information 

on those who are to respond, including 

through the use of appropriate 

automated collection techniques or 

other forms of information technology, 

e.g., permitting electronic submission of 

responses. 

This Notice also lists the following 

information: 

Title of Proposal: Exigent Health and 

Safety Deficiency Correction 

Certification. 

OMB Control Number: 2577–0241. 

Description of the need for the 

information and proposed use: HUD’s 

Uniform Physical Condition Standards 

(UPCS) regulation (24 CFR part 5, 

subpart G) provides that HUD housing 

must be decent, safe, sanitary, and in 

good repair. Public housing agencies 

(PHAs) must maintain housing in a 

manner that meets prescribed physical 

condition standards to be considered 

decent, safe, sanitary, and in good 

repair. The UPCS regulation also 

provides that all area and components 

of the housing must be free of health 

and safety hazards. HUD conducts 

physical inspections of the HUD-funded 

housing to determine if the UPCS 

standards are being met. Pursuant to the 

UPCS inspection protocol, at the end of 

the inspection (or at the end of each day 

of a multi-day inspection) the inspector 

provides the property representative 

with a copy of the ‘‘Notification of 

Exigent and Fire Safety Hazards 

Observed’’ form. Each exigent health 

and safety (EHS) deficiency that the 

inspector observed that day is listed on 

the form. The property representative 

signs the form acknowledging receipt. 

PHAs are to correct EHS deficiencies 

(i.e., emergency work orders) within 24 

hours. PHAs are to notify HUD, using 

the electronic format, within three 

business days of the date of inspection, 

which is the date the PHA was provided 

notice of these deficiencies, that the 

deficiencies were corrected within the 

prescribed time frames. 

Agency form number: None. 

Members of affected public: Public 

Housing Agencies. 

Estimation of the total number of 

hours needed to prepare the information 

collection including number of 

respondents: 1,236 respondents 

annually with one response per 

respondent. Average time per response 

is .44 hours and the total burden hours 

are 333.57. 

Status of the proposed information 

collection: Extension of currently 

approved collection. 

Authority: Section 3506 of the Paperwork 

Reduction Act of 1995, 44 U.S.C. Chapter 35, 

as amended. 

Dated: October 21, 2010. 

Merrie Nichols-Dixon, 

Acting Deputy Assistant Secretary, Office of 

Policy, Program and Legislative Initiatives. 

[FR Doc. 2010–27310 Filed 10–27–10; 8:45 am] 

BILLING CODE 4210–67–P 

DEPARTMENT OF HOUSING AND 

URBAN DEVELOPMENT 

[Docket No. FR–5415–N–14] 

Notice of Availability: Notice of 

Funding Availability (NOFA) for HUD’s 

Fiscal Year 2010 Housing Choice 

Voucher Family Self-Sufficiency 

Program 

AGENCY: Office of the Chief of the 

Human Capital Officer, HUD. 

ACTION: Notice. 

SUMMARY: HUD announces the 

availability on its Web site of the 

applicant information, submission 

deadlines, funding criteria, and other 

requirements for HUD’s Fiscal Year (FY) 

2010 Housing Choice Voucher Family 

Self-Sufficiency (HCV FSS) Program. 

The HCV FSS NOFA makes available 

approximately $60 million under the 

Consolidated Appropriations Act 2010. 

The purpose of the HCV FSS program is 

to promote the development of local 

strategies to coordinate the use of 

assistance under the HCV program with 

public and private resources to enable 

participating families to increase earned 

income and financial literacy, reduce or 

eliminate the need for welfare 

assistance, and make progress toward 

economic independence and selfsufficiency. 


emcdonald on DSK2BSOYB1PROD with NOTICES